| MERCK KGAA O.N. | 134.35 / -0.63% |
| Date/Time | 10/28 / 16:40 |
| Chg. / Chg.(%) | -0.85 / -0.63% |
| Bid | 134.35 / 510 |
| Ask | 134.40 / 204 |
| Open | 133.00 |
| Previous Close | 135.20 |
| High | 136.95 |
| Low | 133.00 |
| Volume [EUR] | 74,823,677.00 |
| Volume [Units] | 555,356 |
| Price fixings | 5697 |
| ISIN | DE0006599905 |
| Security | MRK |
| Exchange | Xetra |
| Type | Stock |
| Exchange | Last | Volume | |
|---|---|---|---|
| Xetra | 134.35 |  |
555,356 |
| Cboe Europe .. | 134.40 | |
180,725 |
| Turquoise | 134.40 | |
153,723 |
| Cboe Europe .. | 134.35 | |
118,570 |
| London Inter.. | 133.95 | |
69,014 |
| TradeGate | 134.900 | |
14,974 |
| Stuttgart | 134.200 | |
4,104 |
| Frankfurt | 134.3000 | |
1,329 |
| gettex | 133.900 | |
693 |
| Borsa Italia.. | 134.60 |  |
471 |
| Düsseldorf | 133.95 | |
130 |
| München | 134.40 | |
61 |
| Hannover | 135.35 | |
45 |
| Nasdaq Other.. | 156.9500 | |
5 |
| Vienna Globa.. | 134.20 | |
0 |
| Hamburg | 133.60 | |
0 |
| Berlin | 133.75 | |
0 |
| Lang & Schwa.. | 134.300 | |
|
| SIX Swiss Ex.. | 130.00 | ||
| SIX Swiss Ex.. | 109.60 | ||
| EUREX | Options | ||
News
- Basilea announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company for ramucirumab in the ongoing FIDES-03 study with derazantinib in gastric cancer
07:15 - GlobeNewswire - Merck revenue rises 1% YoY to $12.6B in Q3
10/27/2020 / 11:56 - TeleTrader - Vaccinex Announces Clinical Collaboration with Merck to Evaluate Pepinemab in Combination with KEYTRUDA® in Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
09/17/2020 / 14:00 - GlobeNewswire - PTA-News: 4SC AG: 4SC expands avelumab supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer<BR/>for further clinical combination study of domatinostat in Merkel cell carcinoma
09/15/2020 / 07:30 - pressetext - NKMax America Announces a Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer
09/09/2020 / 01:00 - GlobeNewswire
Real-time